CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.930
+0.360 (10.08%)
At close: Nov 3, 2025, 4:00 PM EST
4.080
+0.150 (3.81%)
After-hours: Nov 3, 2025, 7:06 PM EST
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover CytomX Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $5.80, which forecasts a 47.58% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $7.00.
Price Target: $5.80 (+47.58%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 2 | 2 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $3.5 → $6 | Buy | Maintains | $3.5 → $6 | +52.67% | Oct 21, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $6 | Buy | Initiates | $6 | +52.67% | Sep 22, 2025 |
| Barclays | Barclays | Buy Initiates $3.5 | Buy | Initiates | $3.5 | -10.94% | Sep 17, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $7 | Buy | Initiates | $7 | +78.12% | Jul 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +27.23% | May 20, 2025 |
Financial Forecast
Revenue This Year
95.07M
from 138.10M
Decreased by -31.16%
Revenue Next Year
44.22M
from 95.07M
Decreased by -53.48%
EPS This Year
0.03
from 0.38
Decreased by -92.82%
EPS Next Year
-0.28
from 0.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 118.7M | 107.1M | |||
| Avg | 95.1M | 44.2M | |||
| Low | 76.0M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -14.1% | 12.7% | |||
| Avg | -31.2% | -53.5% | |||
| Low | -45.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.18 | - | |||
| Avg | 0.03 | -0.28 | |||
| Low | -0.06 | -0.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -52.7% | - | |||
| Avg | -92.8% | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.